EGFR and non-small cell lung carcinoma: The standard first-line treatments for NSCLC with activated EGFR mutations are EGFR tyrosine kinase inhibitors (EGFR-TKIs) like Afatinib, Erlotinib, Gefitinib, Dacomitinib, and Osimertinib, which can achieve significant disease control for a certain period [13].